Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts.
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Depsipeptides
/ administration & dosage
Female
Humans
Lenalidomide
/ administration & dosage
Lymphoma
/ drug therapy
Male
Maximum Tolerated Dose
Middle Aged
Neoplasm Recurrence, Local
/ drug therapy
Oligopeptides
/ administration & dosage
Treatment Outcome
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
01 10 2021
01 10 2021
Historique:
revised:
06
06
2021
received:
17
04
2021
accepted:
02
07
2021
pubmed:
13
7
2021
medline:
28
9
2021
entrez:
12
7
2021
Statut:
ppublish
Résumé
Romidepsin (histone deacetylase inhibitor), lenalidomide (immunomodulatory agent), and carfilzomib (proteasome inhibitor), have efficacy and lack cumulative toxicity in relapsed/refractory lymphoma. We performed two investigator initiated sequential phase I studies to evaluate the maximum tolerated dose (MTD) of romidepsin and lenalidomide (regimen A) and romidepsin, lenalidomide, and carfilzomib (regimen B) in relapsed/refractory lymphoma. Cohorts in T-cell lymphoma (TCL), B-cell lymphoma (BCL) were enrolled at the MTD. Forty-nine patients were treated in study A (27 TCL, 17 BCL, 5 Hodgkin lymphoma (HL)) and 27 (16 TCL, 11 BCL) in study B. The MTD of regimen A was romidepsin 14 mg/m
Identifiants
pubmed: 34251048
doi: 10.1002/ajh.26288
pmc: PMC8811706
mid: NIHMS1765467
doi:
Substances chimiques
Depsipeptides
0
Oligopeptides
0
carfilzomib
72X6E3J5AR
romidepsin
CX3T89XQBK
Lenalidomide
F0P408N6V4
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1211-1222Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Nat Med. 2018 May;24(5):679-690
pubmed: 29713087
J Clin Oncol. 2009 Nov 10;27(32):5404-9
pubmed: 19805688
J Clin Oncol. 2012 Feb 20;30(6):631-6
pubmed: 22271479
Leuk Lymphoma. 2011 Aug;52(8):1585-8
pubmed: 21504290
J Clin Oncol. 2018 Mar 10;36(8):728-734
pubmed: 29341834
Ann Oncol. 2008 May;19(5):964-9
pubmed: 18296419
J Clin Oncol. 2012 Jun 20;30(18):2190-6
pubmed: 22614995
Blood. 2014 Aug 7;124(6):899-906
pubmed: 24963043
J Clin Oncol. 2011 Jun 20;29(18):2598-607
pubmed: 21576639
Br J Haematol. 2010 Feb;148(3):480-2
pubmed: 19863533
Blood. 2012 Mar 15;119(11):2579-89
pubmed: 22262760
Cancer. 2011 Nov 15;117(22):5058-66
pubmed: 21495023
J Clin Oncol. 2016 Dec;34(34):4086-4093
pubmed: 27621400
Clin Cancer Res. 2019 Sep 1;25(17):5271-5283
pubmed: 30979734
Blood. 2017 Jan 26;129(4):473-483
pubmed: 28064239
Cancer Res. 2007 Jan 15;67(2):746-55
pubmed: 17234786
Eur J Cancer. 2013 Sep;49(13):2869-76
pubmed: 23731832
Cancer. 2015 Mar 1;121(5):716-23
pubmed: 25355245
Blood. 2011 Jun 2;117(22):5827-34
pubmed: 21355097
J Clin Oncol. 2011 Mar 20;29(9):1182-9
pubmed: 21245435
Clin Cancer Res. 2015 Oct 15;21(20):4663-75
pubmed: 26116270
J Clin Oncol. 2015 Nov 1;33(31):3635-40
pubmed: 26304886
Blood. 2011 Nov 10;118(19):5119-25
pubmed: 21937701
J Clin Oncol. 2008 Sep 1;26(25):4124-30
pubmed: 18626005
N Engl J Med. 1995 Dec 7;333(23):1540-5
pubmed: 7477169
N Engl J Med. 2006 Oct 5;355(14):1456-65
pubmed: 17021321
Blood. 2014 Feb 20;123(8):1159-66
pubmed: 24335103
J Clin Oncol. 2010 Oct 10;28(29):4485-91
pubmed: 20697094
J Clin Oncol. 2015 Jan 20;33(3):251-7
pubmed: 25135992
Hematol Oncol Clin North Am. 2007 Oct;21(5):841-54
pubmed: 17908623
J Clin Oncol. 2019 May 10;37(14):1188-1199
pubmed: 30897038
Br J Haematol. 2017 Aug;178(3):434-441
pubmed: 28440559
J Clin Oncol. 2009 Nov 10;27(32):5410-7
pubmed: 19826128
J Clin Oncol. 2015 Aug 10;33(23):2492-9
pubmed: 26101246
Haematologica. 2010 May;95(5):794-803
pubmed: 19951978
J Clin Oncol. 2011 Mar 20;29(9):1198-203
pubmed: 21300924
N Engl J Med. 2015 Jan 8;372(2):142-52
pubmed: 25482145
Clin Cancer Res. 2013 Dec 15;19(24):6882-90
pubmed: 24097867
J Clin Oncol. 2012 Jun 20;30(18):2197-203
pubmed: 22547596
Blood Cancer J. 2014 Feb 21;4:e182
pubmed: 24562384
J Clin Oncol. 2006 Jan 1;24(1):166-73
pubmed: 16330674
J Clin Oncol. 2008 Oct 20;26(30):4952-7
pubmed: 18606983
Cancer. 2010 Oct 1;116(19):4541-8
pubmed: 20572046